Stock analysts at StockNews.com assumed coverage on shares of Moleculin Biotech (NASDAQ:MBRX – Get Free Report) in a research report issued to clients and investors on Saturday. The brokerage set a “sell” rating on the stock. Separately, HC Wainwright reissued a “buy” rating and issued a $3.00 target price on shares of Moleculin Biotech in […]
Related Keywords
Walterv Klemp , , Charles Schwab Investment Management Inc , Moleculin Biotech Inc , Citadel Advisors , Atticus Wealth Management , Renaissance Technologies , Moleculin Biotech , Get Free Report , Biotech Stock Down , Schwab Investment Management , Wealth Management , State Street Corp , Street Corp , Moleculin Biotech Daily , Nasdaq Mbrx , Ambrx , Medical , Initiated Coverage , Stocknews Com ,
comparemela.com © 2020. All Rights Reserved.